1282 related articles for article (PubMed ID: 25456363)
21. [Result of treatment for advanced germ cell tumor in the last decade].
Ishioka J; Kageyama Y; Inoue M; Fukui N; Numao N; Saito K; Ichiyanagi N; Tanak M; Hyochi N; Fukuda H; Higashi Y
Nihon Hinyokika Gakkai Zasshi; 2010 Mar; 101(3):539-46. PubMed ID: 20387513
[TBL] [Abstract][Full Text] [Related]
22. Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours.
Lawrence NJ; Chan H; Toner G; Stockler MR; Martin A; Yip S; Wong N; Yeung A; Mazhar D; Pashankar F; Frazier L; McDermott R; Walker R; Tan H; Davis ID; Grimison P;
BMC Cancer; 2018 Aug; 18(1):854. PubMed ID: 30157803
[TBL] [Abstract][Full Text] [Related]
23. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial.
Mead GM; Cullen MH; Huddart R; Harper P; Rustin GJ; Cook PA; Stenning SP; Mason M;
Br J Cancer; 2005 Jul; 93(2):178-84. PubMed ID: 15999102
[TBL] [Abstract][Full Text] [Related]
24. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.
Kaye SB; Mead GM; Fossa S; Cullen M; deWit R; Bodrogi I; van Groeningen C; Sylvester R; Collette L; Stenning S; De Prijck L; Lallemand E; deMulder P
J Clin Oncol; 1998 Feb; 16(2):692-701. PubMed ID: 9469359
[TBL] [Abstract][Full Text] [Related]
25. Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP.
de Wit R; Louwerens M; de Mulder PH; Verweij J; Rodenhuis S; Schornagel J
Int J Cancer; 1999 Dec; 83(6):831-3. PubMed ID: 10597204
[TBL] [Abstract][Full Text] [Related]
26. Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours.
Horwich A; Brada M; Nicholls J; Jay G; Hendry WF; Dearnaley D; Peckham MJ
Eur J Cancer Clin Oncol; 1989 Feb; 25(2):177-84. PubMed ID: 2467806
[TBL] [Abstract][Full Text] [Related]
27. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
28. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
29. Paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) as initial treatment in patients with poor-prognosis germ cell tumors (GCT): a phase II study.
Mardiak J; Sálek T; Sycová-Milá Z; Obertová J; Recková M; Mego M; Hlavatá Z; Brozmanová K; Risnyovzská Z; Svetlovská D; Koza I
Neoplasma; 2007; 54(3):240-5. PubMed ID: 17447857
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors and efficacy of different chemotherapeutic regimens in patients with mediastinal nonseminomatous germ cell tumors.
Fedyanin M; Tryakin A; Mosyakova Y; Pokataev I; Bulanov A; Zakharova T; Polockii B; Garin A; Tjulandin S
J Cancer Res Clin Oncol; 2014 Feb; 140(2):311-8. PubMed ID: 24337455
[TBL] [Abstract][Full Text] [Related]
31. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.
Grimison PS; Stockler MR; Thomson DB; Olver IN; Harvey VJ; Gebski VJ; Lewis CR; Levi JA; Boyer MJ; Gurney H; Craft P; Boland AL; Simes RJ; Toner GC
J Natl Cancer Inst; 2010 Aug; 102(16):1253-62. PubMed ID: 20631341
[TBL] [Abstract][Full Text] [Related]
32. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
[TBL] [Abstract][Full Text] [Related]
33. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
[TBL] [Abstract][Full Text] [Related]
34. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Piperno-Neumann S; Le Deley MC; Rédini F; Pacquement H; Marec-Bérard P; Petit P; Brisse H; Lervat C; Gentet JC; Entz-Werlé N; Italiano A; Corradini N; Bompas E; Penel N; Tabone MD; Gomez-Brouchet A; Guinebretière JM; Mascard E; Gouin F; Chevance A; Bonnet N; Blay JY; Brugières L; ; ;
Lancet Oncol; 2016 Aug; 17(8):1070-1080. PubMed ID: 27324280
[TBL] [Abstract][Full Text] [Related]
35. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
[TBL] [Abstract][Full Text] [Related]
36. The management of poor-prognosis, non-seminomatous germ-cell tumours.
Sirohi B; Huddart R
Clin Oncol (R Coll Radiol); 2005 Oct; 17(7):543-52. PubMed ID: 16238142
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
38. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.
Vidal AD; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
Ann Oncol; 2015 Feb; 26(2):374-7. PubMed ID: 25392157
[TBL] [Abstract][Full Text] [Related]
39. Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.
Loriot Y; Pagliaro L; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Laplanche A; Le Teuff G; Culine S; Fizazi K
Eur J Cancer; 2017 Dec; 87():140-146. PubMed ID: 29149760
[TBL] [Abstract][Full Text] [Related]
40. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.
Fosså SD; Kaye SB; Mead GM; Cullen M; de Wit R; Bodrogi I; van Groeningen CJ; De Mulder PH; Stenning S; Lallemand E; De Prijck L; Collette L
J Clin Oncol; 1998 Feb; 16(2):716-24. PubMed ID: 9469362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
